Keywords: Covance, R&d, Sanofi-Aventis, alliance, Cluzel
Covance enters $2.2 bn R&D alliance with Sanofi-Aventis
Article | 30 September 2010
Contract research organisation Covance has forged a long-term $2.2 billion drug development alliance with French drugmaker Sanofi-Aventis that will see two ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
